Inhibitor and substrate interactions with equilibrative nucleoside transporter 1 (ENT1; SLC29A1) are known to be affected by cysteine-modifying reagents. Given that selective ENT1 inhibitors, such as nitrobenzylmercaptopurine riboside (NBMPR), bind to the N-terminal half of the ENT1 protein, we hypothesized that one or more of the four cysteine residues in this region were contributing to the effects of the sulfhydryl modifiers. Recombinant human ENT1 (hENT1), and the four cysteine-serine ENT1 mutants, were expressed in nucleoside transport-deficient PK15 cells and probed with a series of methanethiosulfonate (MTS) 3 H]2-chloroadenosine transport. The results of this study also indicate that the hENT1-C193S mutant may be useful as a MTSET/MTSESinsensitive transporter for future cysteine substitution studies to define the extracellular domains contributing to the binding of substrates and inhibitors to this critical membrane transporter.
Introduction
Nucleoside salvage pathways rely on the function of nucleoside transporters to facilitate the movement of hydrophilic nucleosides across cell membranes. Adenosine is one of the principal substrates for these transporters, and adenosine receptor-mediated actions on neurotransmission and cardiovascular tone are enhanced by blocking adenosine uptake into cells (Baldwin et al., 2004; Löffler et al., 2007) . Current antiviral and antineoplastic therapies also rely on nucleoside transporters for the cellular uptake of cytotoxic nucleoside analogs (Zhang et al., 2007) . There are two classes of nucleoside transporters: concentrative nucleoside transporters that are sodium-dependent influx symporters and equilibrative nucleoside transporters (ENTs) that are sodium-independent and function by facilitative diffusion (Baldwin et al., 2004; Kong et al., 2004) . The ubiquitously expressed ENT1 (SLC29A1) is the predominant mediator of bidirectional nucleoside flux and is a major regulator of intracellular and extracellular concentrations of nucleosides (Griffiths et al., 1997; Baldwin et al., 2004) . ENT1 was initially characterized by its sensitivity to the high-affinity ligand nitrobenzylmercaptopurine ribonucleoside (NBMPR) and is predicted to possess an 11-transmembrane (TM) topology with an intracellular N terminus and an extracellular C terminus (Griffiths et al., 1997; Hyde et al., 2001) . Human ENT1 (hENT1) consists of 456 amino acids (Fig. 1) , with the region encompassing TM3 to TM6 required for proper function (Sundaram et al., 1998 (Sundaram et al., , 2001a Yao et al., 2002) . This region also contains several residues that are critical for the recognition of inhibitors by hENT1. For example, glycine residues Gly154 (TM4) and Gly179 (TM5) are essential for NBMPR binding and transport activity (SenGupta et al., 2002; SenGupta and Unadkat, 2004) , and modifications at Met89 and Ser160 in TM2 and TM4, respectively, reduce the affinities of NBMPR and adenosine, but not that of dilazep (Endres and Unadkat, 2005) . The attainment of more precise information on the substrate translocation and ligand binding determinants of this important transport protein has been hampered by the fact that, as an integral membrane protein, hENT1 is not readily isolated for biophysical analysis. An approach commonly used for such intransigent proteins is cysteine-scanning mutagenesis to assess the aqueous accessibility of protein domains. This approach requires a clear understanding of the roles of endogenous cysteines in transporter function.
The importance of cysteines in the activity of ENT1 has been well documented. Numerous studies have used the neutral thiol-modifying reagent N-ethylmaleimide (NEM) and the negatively charged p-chloromercuribenzene sulfonate (pCMBS) to react with free sulfhydryls of ENT1 to cause functional changes (Plagemann and Richey, 1974; DahligHarley et al., 1981; Belt, 1983; Tse et al., 1985; Jarvis and Young, 1986; Lee et al., 1995; Vyas et al., 2002) . NEM treatment invariably led to a decrease in both [
3 H]NBMPR binding and transport function. In contrast, pCMBS and similar membrane-impermeable sulfhydryl reagents were generally found to be without effect on NBMPR-sensitive (ENT1) transport function and ligand binding in intact cells, but these reagents could inhibit [ 3 H]NBMPR binding when allowed access to the cytoplasmic side of the membrane (Dahlig-Harley et al., 1981; Jarvis and Young, 1982; Vyas et al., 2002) . In some models, NEM had complex effects on the transporter. In Ehrlich ascites tumor cells, NEM inhibited function and [
3 H]NBMPR binding at low concentrations but enhanced [
3 H]NBMPR binding at higher concentrations (Vyas et al., 2002) . Others have shown different effects depending on the substrate used (Krzystyniak et al., 1988) , and, in some cases, NEM seemed to inhibit only a subset of the total number of ENT1 transporters in the preparation (Lee et al., 1995; Vyas et al., 2002) . There was also considerable variability in the magnitude of effect of the sulfhydryl reagents in past studies, probably reflecting species differences, different cell models, and the presence of mixed populations of ENT subtypes. Overall, though, these data imply that at least two cysteines are important in ENT1 function, one in a hydrophobic region and another in a cytoplasmic hydrophilic domain.
Given that NBMPR has been shown to bind to components of the N-terminal half of the protein (Sundaram et al., 2001a,b) , we hypothesized that one or more of the four cysteine residues in TM2 to TM6 of hENT1 ( Fig. 1) are involved in these documented effects of sulfhydryl reagents on NBMPR binding. The aim of this study was to examine 37°C in a 5% CO 2 -humidified atmosphere. mRNA was collected from each cell clone and tested for the presence of the respective hENT1 transcript by reverse transcription-polymerase chain reaction and sequencing.
Cell Membrane Preparations. PK15-NTD cells expressing wild-type hENT1 and variants were harvested from T175 flasks by 0.05% trypsin/0.53 mM EDTA. Cells were swollen in hypotonic (5 mM) sodium phosphate buffer, containing a mammalian protease inhibitor cocktail (Set 1; Calbiochem-EMD4Biosciences, Gibbstown, NJ), for 30 min on ice. Cells were then fragmented using a Sonic Dismembrator model 150 (Thermo Fisher Scientific, Waltham, MA) for 30 s and centrifuged at 3000g for 10 min at 4°C to pellet nuclei and unbroken cells. The supernatant containing the crude cell membranes was then centrifuged for 30 min at 30,000g at 4°C. This membrane pellet was suspended in 5 mM sodium phosphate buffer and protease inhibitor cocktail mix, and protein content was determined by the Bradford colormetric assay (Bradford, 1976) .
Treatment with MTS Reagents. Cells were harvested from culture flasks using 0.05% trypsin/0.53 mM EDTA, diluted with media containing 10% (v/v) bovine growth serum, collected by centrifugation at 6000g, and washed twice with PBS (137 mM NaCl, 6.3 mM Na 2 HPO 4 , 2.7 mM KCl, 1.5 mM KH 2 PO 4 , 0.5 mM MgCl 2 ⅐6H 2 O, and 0.9 mM CaCl⅐2H 2 O, pH 7.4, 22°C). Cell pellets were then suspended in PBS, sodium-free N-methylglucamine (NMG) buffer (pH 7.25, containing 140 mM NMG, 5 mM KCl, 4.2 mM KHCO 3 , 0.36 mM K 2 HPO 4 , 0.44 mM KH 2 PO 4 , 10 mM HEPES, 0.5 mM MgCl 2 , and 1.3 mM CaCl 2 ) or 50 mM Tris (pH 6.0, 7.2, or 8.2), depending on experimental requirements. Cell suspensions were incubated with 0.1% dimethyl sulfoxide (DMSO, control) or MTS reagents dissolved in DMSO. Cell suspensions were then washed three times with PBS or NMG, depending on assay type, by centrifugation to remove unreacted MTS reagents. A concentration/time course analysis was done with each MTS reagent to optimize the concentration and incubation period needed for a maximal distinguishable effect. In some cases, 10 nM NBMPR or 1 mM adenosine was included in the MTS treatment protocol to assess the ability of these ENT1 ligands to protect the cells from MTS modification.
[ 3 H]NBMPR Binding. Cells (ϳ75 ϫ 10 3 cells/assay) were suspended in PBS and incubated with [ 3 H]NBMPR for 45 min at room temperature (ϳ22°C). Cells were collected on Whatman (Clifton, NJ) Binder-Free Glass Microfiber Filters (type 934-AH) using a 24-port Brandel (Montreal, QC, Canada) cell harvester, washed twice with Tris-HCl buffer (10 mM Tris, pH 7.4, 4°C), and analyzed for 3 H content using standard liquid scintillation counting techniques. Specific binding was defined as total binding minus cell-associated [ 3 H]NBMPR in the presence of 10 M NBTGR (nonspecific binding).
[ 3 H]2-Chloroadenosine Uptake. Uptake was initiated by the addition of cells (ϳ750 ϫ 10 3 cells/assay) suspended in NMG buffer to [ 3 H]2-chloroadenosine layered over 200 l of silicon/mineral oil [21:4 (v/v)] in 1.5-ml microcentrifuge tubes. Parallel assays were conducted in the absence (total uptake) and presence (nonmediated uptake) of 5 M NBMPR/dipyridamole; transporter-mediated uptake of substrate was calculated as the difference between these two conditions. After a defined incubation time, uptake was terminated by centrifugation of cells through the oil layer (10 s at 12,000g). Aqueous and oil layers were removed by aspiration, and cell pellets were digested in 1 M sodium hydroxide overnight (12-16 h). An aliquot of the digest was removed and analyzed for 3 H content using standard liquid scintillation counting techniques. Uptake data are presented as pmol per l of intracellular volume after correction for the amount of extracellular 3 H in the cell pellet. Total volume was determined by incubating cells with [ 3 H]water for 3 min and processed as above. Extracellular water space was estimated by extrapolation of the linear time course of nonmediated uptake to zero time. Using this method, it was determined that 1 l of intracellular water corresponded to 414 Ϯ 128 ϫ 10 3 (n ϭ 4) PK15-hENT1 cells; this number was used to calculate ENT1 translocation rates from the V max /B max ratios for each ENT1-transfected cell model. (Fig. 3A) . Membranes prepared from the PK15-ENT1 transfectants had an affinity for [ 3 H]NBMPR of 0.14 Ϯ 0.02 nM and bound 1.2 Ϯ 0.11 pmol/mg protein (Fig. 3B ). Dithiothreitol treatment (2 mM, 10 min, room temperature) of the PK15-hENT1 cells had no effect on the binding of [ 3 H]N-BMPR (data not shown), suggesting that existing sulfhydryl bonds between cysteine residues were not contributing to protein structure of importance to NBMPR binding. The known ENT1 antagonists, dipyridamole, dilazep, and draflazine inhibited the binding of [ (Fig. 3C ). PK15 cells transfected with hENT1 accumulated [ 3 H]2-chloroadenosine via a NBMPR-sensitive transport process with a V max of 9.5 Ϯ 0.8 pmol ⅐ l Ϫ1 ⅐ s Ϫ1 and K m of 71 Ϯ 8 M (Fig.  3D) . Dipyridamole, dilazep, NBMPR, and NBTGR inhibited [ 3 H]2-chloroadenosine influx with K i values of 111 Ϯ 35, 10.4 Ϯ 1.7, 2.0 Ϯ 1.0, and 8.6 Ϯ 1.9 nM, respectively. These characteristics are compatible with a fully functional ENT1-type transporter and are similar to previous reports of hENT1 constructs expressed in this cell model (Ward et al., 2000) indicating that the N terminal FLAG epitope did not significantly affect transporter function.
Results

Characteristics of hENT1
Effects of MTS Reagents on hENT1 Function and Ligand Binding. PK15 cells expressing hENT1 were incu- Table 3 . D, the concentration-dependent uptake of [ bated for different time periods with a range of concentrations of MMTS, MTSET, and MTSES. From these initial studies it was determined that the maximal effect of each of the sulfhydryl reagents could be realized with 10-min incubation at room temperature with 1 mM MMTS and 5 mM MTSET or MTSES. The effect of NEM was also tested in this system to allow comparison with previously published studies. As seen for endogenous ENT1 in human erythrocytes (Vyas et al., 2002) , the membrane-permeable NEM (300 M for 30 min on ice) caused significant inhibition (60 Ϯ 8% decrease in B max ) of [ 3 H]NBMPR binding to the PK15-hENT1 cells along with a 2.2 Ϯ 0.7-fold increase in K d (Fig. 4A) . MMTS, which like NEM is membrane-permeable, caused a significant 62 Ϯ 11% increase in the number of NBMPR binding sites in intact cells with no change in binding affinity (Table 1 ; Fig. 4B ). However, in isolated membranes prepared from these cells, MMTS inhibited binding by approximately 30% (Table 2 ; Fig. 4C ). To investigate further the difference in MMTS effect on intact cells (enhancement) versus membranes (inhibition), intact cells were treated with MMTS (or DMSO as control) and then used to prepare isolated membranes for analysis of [ (Fig. 6B ). On the other hand, the ability of substrates such as adenosine and inosine to inhibit [ 3 H]2-chloroadenosine uptake was unaffected by MMTS treatment (Fig. 6C ). Unlike that seen for [ 3 H]2-chloroadenosine uptake, MMTS treatment had no effect on the ability of dipyridamole, dilazep, or draflazine to inhibit the binding of [ 3 H]NBMPR to wild-type hENT1 (Table 3) . Coincubation of cells with MMTS and either adenosine (1 mM) or NBMPR (10 nM) produced a similar enhancement of [ 3 H]NBMPR binding in intact cells as did MMTS alone (data not shown). However, NBMPR, but not adenosine, did provide a partial protection (20 Ϯ 6% versus 33 Ϯ 3% inhibition in the presence and absence of 10 nM NBMPR, respectively) against the attenuating effect of MMTS on [ 3 H]NBMPR binding in isolated membranes (Fig. 7) .
The membrane-impermeable MTSES had no effect on [ Fig. 8A ). MTSET, on the other hand, which is also membrane-impermeable, but of the opposite charge to MTSES, produced a slight, but significant, decrease (13 Ϯ 4%) in [
3 H]NBMPR binding in intact cells (Table 1 ; Fig. 8B ), H]N-BMPR in the presence and absence of 10 M NBTGR to define total and nonspecific binding. Data shown are the specific binding (sites/cell), calculated as the total minus the nonspecific binding. Each point is the mean Ϯ S.E.M. from at least five experiments conducted in duplicate. C, PK15-hENT1 cells were treated with either 1 mM MMTS (E) or 0.1% DMSO (F; vehicle control) for 10 min at room temperature, washed extensively, and then processed to obtain crude membrane preparations as described under Materials and Methods. In parallel, untreated PK15-hENT1 cells were processed to obtain isolated membranes, and then these membranes were treated with either 1 mM MMTS (Ⅺ) or 0.1% DMSO (f) for 10 min at room temperature. Membranes were then incubated with a range of concentrations of [ decreased binding to isolated membranes (by approximately 60% to 0.42 Ϯ 0.18 pmol/mg) ( Fig. 9C ), and this effect was significantly greater than that observed for any of the other hENT1 mutants tested in this study (Table 1 ). In addition, unlike that seen for the wild-type hENT1 and other mutants, MMTS did not affect the rate of [ 3 H]2-chloroadenosine uptake in the C193S cells (Fig. 9D) . Likewise, the membrane-impermeable reagents had no effect on either [
3 H]NBMPR binding or [ 3 H]2-chloroadenosine up- (Table 1 ). The affinities of dipyridamole and draflazine for inhibiting [ 3 H]NBMPR binding to the C193S mutant were similar to those seen for the wild-type hENT1; whereas the affinity of the [ 3 H]NBMPR binding site for dilazep (5.2 Ϯ 1.1 nM) was significantly lower in the C193S mutant relative to wild-type hENT1. Furthermore, treatment of these cells with MMTS shifted the affinity of the binding site for dipyridamole from 32 Ϯ 10 to 111 Ϯ 32 nM and tended toward an increase in the affinity of both dilazep and draflazine, although statistical significance was not attained for these latter two inhibitors (Table 3) . uptake were 77 Ϯ 10 M and 22 Ϯ 3 pmol ⅐ l Ϫ1 ⅐ s Ϫ1 , respectively, resulting in a translocation rate of 115 Ϯ 30 molecules/ENT1/s, which is significantly greater than that of wild-type hENT1. The cells transfected with hENT1-C213S seemed to increase in their transport and binding capacity with time. In this way they were distinct from the other hENT1-mutants tested, which remained relatively consistent in their binding and transport capacity throughout the study ( Fig. 9F ).
Mutation of Cys213. hENT1-C213S cells bound [
MTSET inhibited [
3 H]NBMPR binding by a significant 18 Ϯ 12%, but had no effect on [ 3 H]2-chloroadenosine uptake (Table 1; Fig. 9F ), similar to that seen for the C193S mutant. MTSES had no effect on either [
3 H]NBMPR binding or [ 3 H]2-chloroadenosine uptake in the C213S mutants (Table 1) . Likewise, the inhibitors dipyridamole, dilazep, and draflazine had similar affinities for the [ 3 H]NBMPR binding site in the C213S mutant relative to wild-type hENT1, and treatment of the cells with MMTS had no effect on these inhibitor affinities (Table 3) . Table  1) . The C222S cells were also similar to the C87S and C213S mutants and the hENT1 wild-type cells in that MMTS caused a significant decrease (53 Ϯ 21%) in the maximal rate of [ 3 H]2-chloroadenosine uptake (Fig. 9H) . Neither MTSET nor MTSES affected [ 3 H]2-chloroadenosine uptake by the hENT1-C222S cells (Table 1 ). The hENT1-C222S mutant was also the only one of those studied that did not show a significant decrease in (Table 2 ; Fig. 9G ). The inhibitors dipyridamole, dilazep, and draflazine had similar affinities for the [ 3 H]NBMPR binding site in the C222S mutant relative to wild-type hENT1, and treatment of the cells with MMTS had no effect on these inhibitor affinities (Table 3) .
Discussion
Each of the hENT1 cysteine mutants were transport-capable and bound [ 3 H]NBMPR with high affinity. The number of [ 3 H]NBMPR binding sites per cell ranged from 180 to 520 ϫ 10 3 sites, which is similar to the densities of endogenous ENT1 reported for various transformed cells lines (Belt et al., 1993; Griffith and Jarvis, 1996) . There were, however, significant differences among the mutants in the apparent translocation rate of the ENT1 transporter (molecules of substrate per ENT1 transporter per s). It has been established that NBMPR binds specifically to ENT1 proteins (Bone et al., 2010), such that [ 3 H]NBMPR B max can be used as a measure of the number of ENT1 transporters expressed in a cell model . However, NBMPR is membrane-permeable and would interact with ENT1 proteins regardless of their cellular location (Paproski et al., 2010) , but only those transporters located in the plasma membrane would contribute to the rate of [ 3 H]2-chloroadenosine uptake. Therefore, changes in the apparent ENT1 translocation rate, as calculated in this study, may reflect changes in the distribution of functional ENT1 proteins to the plasma membrane relative to intracellular compartments. Preliminary immunofluorescence studies indicated that the hENT1 protein was widely distributed throughout the cytoplasm of these cells; however, relative distribution to the plasma membrane could not be discerned using this approach (data not shown). Another possibility is that the mutation is changing the substrate translocation ability of the individual ENT1 proteins. However, the K m of 2-chloroadenosine for the transporter was similar in the wild-type protein and the cysteine mutants, suggesting that the integrity of the substrate translocation site/mechanism was not affected by these mutations. Therefore, current data supports the first possibility of differential distribution. Thus, based on the calculated translocation rates it would seem that wild-type hENT1 and the hENT1-C193S cell mutant had relatively more of the ENT1 protein expressed in intracellular compartments leading to a lower apparent translocation rate (ϳ30 molecules/ENT1/s) than did the C87S, C231S, and C222S mutants (ϳ70 molecules/ENT1/s). These differences in translocation rates did not correlate with the absolute level of ENT1 expression (based on [ 3 H]NBMPR B max ), indicating that the differential distribution was not caused by "overexpression," but rather may reflect differences in membrane targeting.
In general, each of the cysteine mutants was similar to wild-type hENT1 with respect to inhibitor affinities. However, two significant differences were noted: 1) the C87S mutant had approximately a 3-fold lower affinity for dipyridamole, and 2) the C193S mutant had approximately a 3-fold lower affinity for dilazep (see Table 3 ). Previous investigators have shown that mutation of Met89 and Leu92 in TM2, which are near the Cys87 residue mutated in this study, reduced the affinity of ENT1 for NBMPR and dilazep, but not dipyridamole (Endres et al., 2004; Endres and Unadkat, 2005) . Although dilazep, draflazine, and dipyridamole may share overlapping binding sites, each inhibitor could engage a distinct point of contact and thus react differently to different local changes in amino acid structure.
MTS reagents were then tested for their effects on [ 3 H]N-BMPR binding and [ 3 H]2-chloroadenosine uptake by intact cells and for their effects on [ 3 H]NBMPR binding to isolated membranes prepared from these cells. Three reagents were used: 1) MMTS, which is considered to be a neutral membrane-permeable reagent (like NEM), 2) MTSES, a negatively charged membrane-impermeable reagent, and 3) MTSET, a positively charged membrane-impermeable reagent (Fig. 2) . We found that 10-min incubation at room temperature with 1 mM MMTS or 5 mM MTSET/MTSES produced the most robust changes in hENT1 activity; further incubation times had no additional impact on transport binding/function. These incubation conditions are consistent with those used by others to study the effects of MTS reagents on other membrane proteins (Akabas et al., 1992; Chen et al., 1997; Karlin and Akabas, 1998; Lambert et al., 2000; Xu et al., 2000; Ren et al., 2001) .
The ability of MMTS to enhance the binding of [ 3 H]N-BMPR to intact cells expressing hENT1 was a novel and intriguing finding. NBMPR is specific for ENT1 (Bone et al., 2010) , and the protein is considered to have only a single binding site for NBMPR (Jarvis and Young, 1980; Young and Jarvis, 1985) . Thus, these data imply that MMTS treatment enhanced the accessibility of a population of ENT1 proteins to NBMPR. However, the cysteine being modified by MMTS to cause this enhancement is not part of the NBMPR or substrate binding domain because neither NBMPR nor adenosine could protect against this MMTS-induced increase. [ 3 H]NBMPR would be expected to get access to all cellular compartments over the course of the 45-min incubation period. Therefore, the increase cannot be attributed to an increased trafficking of the hENT1 protein to the plasma membrane. Given the relatively short incubation times (10 min) of the cells with MMTS and the fact that the cells were at room temperature (ϳ22°C), the increase is also unlikely to be caused by increased transcription/translation. This enhancement of (Fig. 4C ), but did inhibit [
3 H]NBMPR binding to isolated membranes. These results are consistent with the lack of effect of pCMBS (also negatively charged) on binding and transport in intact cells in previous studies Young, 1982, 1986; Tse et al., 1985; Vyas et al., 2002) . The inhibitory activity of MTSES on [ 3 H]NBMPR binding in the absence of an intact cell membrane indicates that there is an additional cysteine of importance to binding integrity that is accessible only from the cytoplasmic aqueous environment. NBMPR binds to extracellular domains of hENT1; thus, the effect of modifying an intracellular cysteine is likely indirect via a change in ENT1 protein conformation.
Treatment with MTSET, but not MTSES, caused a small, but significant (13 Ϯ 4%), decrease in the number of [ 3 H]N-BMPR binding sites when assessed in intact cells and enhanced the V max of [ 3 H]2-chloroadenosine uptake. Both MTSES and MTSET are charged membrane-impermeable reagents and should react only with cysteines in intact cells that are accessible from the extracellular aqueous media. A significant chemical difference between MTSES and MTSET is that the former is anionic and the latter cationic. This suggests the involvement of a cysteine accessible to the extracellular aqueous region that may be positioned within a negatively charged environment. We propose that Cys193 is responsible for these effects of MTSET and may also be responsible for mediating the effect of MMTS on [ 3 H]2-chloroadenosine uptake. Cys193 is located toward the extracellular end of TM5, making it potentially accessible to extracellular hydrophilic agents. Mutation of Cys193 to serine eliminated both the inhibitory effects of MMTS and the enhancing effects of MTSET on [ 3 H]2-chloroadenosine influx and eliminated the effect of MTSET on [ 3 H]NBMPR binding seen in the wild-type hENT1-transfected cells. It must be noted, however, that the mutation of Cys87 to serine also slightly reduced the effect of MTSET on [ 3 H]NBMPR binding in intact cells. Likewise, the mutation of Cys213 to serine caused a minor reduction in the ability of MTSET to enhance [ 3 H]2-chloroadenosine uptake. However, only the Cys193 mutation eliminated all of the effects of MTS reagents on The results of this study also suggest that the hENT1-C193S mutant may be useful as a MTSET/MTSES-insensitive transporter for future cysteine substitution studies to define the extracellular domains contributing to the binding of substrates and inhibitors to this critical membrane transporter.
